. . "Takayasu Tsuchida, Haruo Uchibori, Yoshitaka Nishimoto, \"Process and microorganism for producing L-ornithine by Corynebacterium, Brevibacterium, or Athrobacter.\" U.S. Patent US5188947, issued January, 1970."@en . "Used for nutritional supplementation, also for treating dietary shortage or imbalance. It has been claimed that ornithine improves athletic performance, has anabolic effects, has wound-healing effects, and is immuno-enhancing."@en . "L-Ornithine is metabolised to L-arginine. L-arginine stimulates the pituitary release of growth hormone. Burns or other injuries affect the state of L-arginine in tissues throughout the body. As De novo synthesis of L-arginine during these conditions is usually not sufficient for normal immune function, nor for normal protein synthesis, L-ornithine may have immunomodulatory and wound-healing activities under these conditions (by virtue of its metabolism to L-arginine)."@en . . . "70-26-8"@en . "Absorbed from the small intestine via a sodium-dependent active transport process"@en . . "(S)-\u03B1,\u03B4-diaminovaleric acid"@en . . "Oral, rat LD₅₀ = 10000 mg/kg"@en . . . "Ornithine is an amino acid produced in the urea cycle by the splitting off of urea from arginine. It is a central part of the urea cycle, which allows for the disposal of excess nitrogen. L-Ornithine is a precursor of citrulline and arginine."@en . . . . . "(S)-alpha,delta-Diaminovaleric acid"@en . . . . . . " "@en . . . . . "L-Ornithine"@en . "(S)-2,5-diaminovaleric acid"@en . "nutraceutical"@en . . "L-Ornithine"@en . . . "(S)-ornithine"@en . . "(S)-2,5-Diaminopentanoate"@en . . . "approved"@en . . . "Humans and other mammals"@en . . . . . . . "(S)-2,5-Diaminopentanoic acid"@en . . . . . . . .